A. Schrag, Y. Ben-shlomo, and N. Quinn, Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study, Lancet, vol.354, pp.1771-1772, 1999.

U. Nath, Y. Ben-shlomo, and R. G. Thomson, The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK, Brain, vol.124, pp.1438-1449, 2001.

J. H. Bower, D. M. Maraganore, S. K. Mcdonnell, and W. A. Rossa, Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Neurology, vol.49, pp.1284-1288, 1976.

M. Kawashima, M. Miyake, M. Kusumi, Y. Adachi, and K. Nakashima, Prevalence of progressive supranuclear palsy in Yonago, Mov Disord, vol.19, pp.1239-1240, 2004.

A. Rojo, R. S. Pernaute, and A. Fontán, Clinical genetics of familial progressive supranuclear palsy, Brain, vol.122, pp.1233-1245, 1999.

S. Fujioka, A. A. Algom, and M. E. Murray, Similarities between familial and sporadic autopsy-proven progressive supranuclear palsy, Neurology, vol.80, pp.2076-2078, 2013.

K. B. Baker and E. B. Montgomery, Performance on the PD test battery by relatives of patients with progressive supranuclear palsy, Neurology, vol.56, pp.25-30, 2001.

G. U. Höglinger, N. M. Melhem, and D. W. Dickson, Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy, Nat Genet, vol.43, pp.699-705, 2011.

M. Baker, I. Litvan, and H. Houlden, Association of an extended haplotype in the tau gene with progressive supranuclear palsy, Hum Mol Genet, vol.8, pp.711-715, 1999.

A. M. Pittman, A. J. Myers, and J. Duckworth, The structure of the tau haplotype in controls and in progressive supranuclear palsy, Hum Mol Genet, vol.13, pp.1267-1274, 2004.

H. Houlden, M. Baker, and H. R. Morris, Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype, Neurology, vol.56, pp.1702-1706, 2001.

R. Rademakers, S. Melquist, and M. Cruts, High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy, Hum Mol Genet, vol.14, pp.3281-3292, 2005.

A. J. Myers, A. M. Pittman, and A. S. Zhao, The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts, Neurobiol Dis, vol.25, pp.561-570, 2007.

L. I. Golbe, R. S. Rubin, and R. P. Cody, Follow-up study of risk factors in progressive supranuclear palsy, Neurology, vol.47, pp.148-154, 1996.

J. S. Vidal, M. Vidailhet, P. Derkinderen, T. D. De-gaillarbois, C. Tzourio et al., Risk factors for progressive supranuclear palsy: a case-control study in France

, J Neurol Neurosurg Psychiatry, vol.80, pp.1271-1274, 2009.

L. I. Golbe, The epidemiology of progressive supranuclear palsy, Handb Clin Neurol, vol.89, pp.457-459, 2008.

F. E. Lepore, J. C. Steele, and T. A. Cox, Supranuclear disturbances of ocular motility in Lytico-Bodig, Neurology, vol.38, pp.1849-1853, 1988.

J. Miklossy, J. C. Steele, and S. Yu, Enduring involvement of tau, beta-amyloid, alpha-synuclein

D. Caparros-lefebvre, L. I. Golbe, and V. Deramecourt, A geographical cluster of progressive supranuclear palsy in northern France, Neurology, vol.85, pp.1293-1300, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-02460488

P. A. Cox and O. W. Sacks, Cycad neurotoxins, consumption of flying foxes, and ALS-PDC disease in Guam, Neurology, vol.58, pp.956-959, 2002.

D. Caparros-lefebvre, N. Sergeant, and A. Lees, Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy, Brain, vol.125, pp.801-811, 2002.

J. C. Rucker, J. Steven, and . Frucht,

, Study funding: No targeted funding reported. Disclosure: The authors report no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures. pathology in the amyotrophic lateral sclerosis/parkinsonismdementia complex of Guam (ALS/PDC), Acta Neuropathol, vol.116, pp.625-637, 2008.

M. J. Winton, S. Joyce, and V. Zhukareva, Characterization of tau pathologies in gray and white matter of Guam parkinsonism-dementia complex, Acta Neuropathol, vol.111, pp.401-412, 2006.

M. Arif, S. F. Kazim, I. Grundke-iqbal, R. M. Garruto, and K. Iqbal, Tau pathology involves protein phosphatase 2A in parkinsonism-dementia of Guam, Proc Natl Acad Sci, vol.111, pp.1144-1149, 2014.

D. Caparros-lefebvre, N. Sergeant, and A. Lees, Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy, Brain, vol.125, pp.801-811, 2002.

D. Caparros-lefebvre and A. Elbaz, Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study. Caribbean Parkinsonism Study Group, Lancet, vol.354, pp.281-286, 1999.

M. Höllerhage, A. Matusch, and P. Champy, Natural lipophilic inhibitors of mitochondrial complex I are candidate toxins for sporadic neurodegenerative tau pathologies, Exp Neurol, vol.220, pp.133-142, 2009.

, Basol Recherche. Available at, 2015.

I. Litvan, Y. Agid, and D. Calne, Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP International Workshop, Neurology, vol.47, pp.1-9, 1996.

E. Grober, H. Buschke, H. Crystal, S. Bang, and R. Dresner, Screening for dementia by memory testing, Neurology, vol.38, pp.900-903, 1988.

B. Dubois, A. Slachevsky, I. Litvan, and B. Pillon, The FAB: a frontal assessment battery at bedside, Neurology, vol.55, pp.1621-1626, 2000.

T. Thomas-danguin, C. Rouby, and G. Sicard, Development of the ETOC: a European test of olfactory capabilities, Rhinology, vol.41, pp.142-151, 2003.

F. Lhermitte and B. Ducarne, Plan of clinical examination of aphasic subjects, Rev Prat, vol.15, pp.2365-2374, 1965.

N. Sergeant, J. P. David, D. Lefranc, P. Vermersch, A. Wattez et al., Different distribution of phosphorylated tau protein isoforms in Alzheimer's and Pick's diseases, FEBS Lett, vol.412, pp.578-582, 1997.

N. Sergeant, B. Sablonnière, and S. Schraen-maschke, Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1, Hum Mol Genet, vol.10, pp.2143-2155, 2001.

, Base de donees: Commune de Wattrelos, Institut national de la statistique et des études économiques, 2015.

, Base de donees: Commune de Leers, Institut national de la statistique et des études économiques, pp.5-59339, 2015.

L. I. Golbe and P. A. Ohman-strickland, A clinical rating scale for progressive supranuclear palsy, Brain, vol.130, pp.1552-1565, 2007.

D. R. Williams, R. De-silva, and D. C. Paviour, Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism, Brain, vol.128, pp.1247-1258, 2005.

I. Litvan, J. J. Hauw, and J. J. Bartko, Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders, J Neuropathol Exp Neurol, vol.55, pp.97-105, 1996.

S. Arpadjan, G. Celik, S. Ta?kesen, and S. Güçer, Arsenic, cadmium and lead in medicinal herbs and their fractionation, Food Chem Toxicol, vol.46, pp.2871-2875, 2008.

S. Javied, S. Waheed, N. Siddique, M. M. Chaudhry, N. Irfan et al., Arsenic pollution from phosphogypsum produced at Multan, Pakistan, Nucleus, vol.46, pp.219-224, 2009.

, BrainPAC BrainPAC is the American Academy of Neurology's federal political action committee

, Since its inception, nearly 3,000 AAN members have contributed $1,500,000 to BrainPAC

, ? BrainPAC will contribute $600,000 to candidates running for Congress in, 2014.

, During the 2012 congressional campaign, 89 percent of candidates supported by BrainPAC won their elections

, BrainPAC supports both Democrats and Republicans who support issues important to the practice of neurology and the care of patients with neurologic conditions. US AAN members are invited to learn more at BrainPAC.org